Gene Therapies to Slow or Stop the Neurodegenerative Process
At Prevail Therapeutics, we are developing a pipeline of gene therapies to slow or stop the underlying disease process for patients with Parkinson’s disease and other neurodegenerative disorders. We are leveraging recent breakthroughs in human genetics that point to potential disease-modifying targets for neurodegenerative diseases. Our programs utilize a precision medicine approach targeting patient populations with urgent unmet needs, where there are currently no available therapies that modify the progressive course of their disorders.
Prevail was founded in a collaborative effort by Asa Abeliovich, M.D., Ph.D., OrbiMed and The Silverstein Foundation for Parkinson’s with GBA, who shared a common vision: to eradicate Parkinson’s disease and related disorders. Through a partnership with REGENXBIO, we are utilizing the NAV AAV9 vector technology to advance a pipeline of gene therapy programs. We are developing our AAV9-based gene therapies for genetically defined patient populations, which we believe will increase the probability of creating disease-modifying therapies that improve patient outcomes.
Prevail was launched in 2017 with a world-class leadership team, partners and investors. We are headquartered in New York City at the Alexandria Center for Life Science. In 2021 Prevail Therapeutics was acquired by Eli Lilly and Company, and is now a wholly owned subsidiary of Eli Lilly. For information please visit the www.lilly.com website.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10.
REGENXBIO and its third-party NAV Technology Platform licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.
Prevail has exclusive worldwide license agreements with REGENXBIO to develop and commercialize gene therapy products using REGENXBIO’s NAV AAV9 vector to deliver the genes contained in PR001, PR006 and PR004.
The Silverstein Foundation for Parkinson’s with GBA
The Silverstein Foundation for Parkinson’s with GBA is a non-profit organization that invests in cutting edge research with the goal of discovering new therapies for the treatment of Parkinson's disease in glucocerebrosidase (GBA1) mutation carriers. The Silverstein Foundation was founded in 2017 by Jonathan Silverstein, General Partner and Co-Head of Global Private Equity at OrbiMed, following his own diagnosis of Parkinson’s disease and learning he was a carrier of the GBA mutation.
Jonathan and The Silverstein Foundation helped form Prevail in 2017 to bring forward curative therapies for patients.